Free Trial
NASDAQ:SCLXW

Scilex (SCLXW) Stock Price, News & Analysis

Scilex logo
$0.11 +0.02 (+18.29%)
As of 06/13/2025 03:11 PM Eastern

About Scilex Stock (NASDAQ:SCLXW)

Key Stats

Today's Range
$0.09
$0.11
50-Day Range
$0.05
$0.13
52-Week Range
$0.04
$0.53
Volume
10,265 shs
Average Volume
7,571 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Receive SCLXW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter.

SCLXW Stock News Headlines

Will I be blacklisted?
The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washington… even Trump’s obsession with seizing Greenland. There’s a singular force that connects the dots… And it could threaten to transform American life – and your wealth – forever.
Scilex announces approval of NDS from Health Canada for ELYXYB
See More Headlines

SCLXW Stock Analysis - Frequently Asked Questions

Scilex's stock was trading at $0.21 at the beginning of the year. Since then, SCLXW shares have decreased by 49.2% and is now trading at $0.1067.
View the best growth stocks for 2025 here
.

Shares of SCLXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
NASDAQ:SCLXW
Fax
N/A
Employees
105
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50.71 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:SCLXW) was last updated on 6/14/2025 by MarketBeat.com Staff
From Our Partners